The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahashi, C.
Right arrow Articles by Vella, A. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, C.
Right arrow Articles by Vella, A. T.
The Journal of Immunology, 1999, 162: 5037-5040.
Copyright © 1999 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: 4-1BB Is a Bona Fide CD8 T Cell Survival Signal1

Chikara Takahashi*, Robert S. Mittler{dagger} and Anthony T. Vella2,*

* Department of Microbiology, Oregon State University, Corvallis OR 97331; and {dagger} Department of Immunology and Inflammation, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08540


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
After recognition of Ag/MHC and ligation of a costimulatory molecule, resting T cells will clonally expand and then delete to very low levels. Previously, it was shown that deletion can be prevented by coinjection of cytokines or proinflammatory agents such as adjuvants. Here, we demonstrate that ligation of 4-1BB blocks deletion of superantigen-activated T cells in the absence of adjuvant or additional cytokine treatment. Nearly 10 times as many staphylococcal enterotoxin A-specific T cells were detected in the spleens of mice injected 21 days previously with staphylococcal enterotoxin A and an agonist anti-4-1BB Ab compared with mice given staphylococcal enterotoxin A and a control IgG. Even though both CD4- and CD8-activated T cells expressed 4-1BB, a higher proportion of CD8 T cells were rescued compared CD4 T cells. These data suggest that although 4-1BB provides costimulation, it may also promote long-term T cell survival.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
For years it has been known that T cells require two signals for full activation (1, 2). Ag presented in the context of MHC is signal one and a costimulatory receptor provides the second signal. CD28 and its ligands CD80 and CD86 have been the most extensively studied. It is documented that CD28 ligation helps T cells to proliferate probably by driving the production of IL-2 (3, 4, 5). Thus, it is surprising that ligation of CD28 in vivo on Ag-activated T cells does not block peripheral T cell deletion (6, 7). This is the case even when APC have been activated in vivo by CD40 ligation (6), which potently enhance B7 expression on APC (8). Therefore, the likely role for CD28-mediated costimulation in vivo is the enhancement of clonal expansion and possibly short-term survival.

In many cases, the use of adjuvants are thought to be the difference between the induction of tolerance vs immunity. Specifically, it has been proposed that a "danger" signal can impede tolerance induction and promote long-term immunity (9). Recently, it has been shown that LPS can block superantigen (SAg)3-induced deletion consistent with the danger theory (10). These data suggest that proinflammatory factors promote long-term survival of Ag-activated T cells in vivo. Additionally, it is clear that IL-2 and IL-4 therapy can inhibit deletion of activated T cells (11, 12). Therefore, Ag-activated T cells may die in vivo by failing to acquire growth factors.

To examine how T cells avoid death in vivo after exposure to SAg, we examined the possibility that other costimulatory molecules may function differently than CD28. 4-1BB is a member of the TNF receptor family and its ligand 4-1BB ligand is a member of the TNF family (13, 14). 4-1BB has been shown to be a potent costimulatory molecule for CD8 T cells by enhancing cytokine production, and proliferative and cytolytic activity (15, 16, 17). Functionally, this receptor/ligand pair can facilitate anti-tumor activity (18). Thus, 4-1BB is a costimulatory molecule that heightens CD8 T cell function.

We report that 4-1BB expression on SAg-activated T cells is rapid and differential between CD4 and CD8 subpopulations. After ligation of 4-1BB on SAg-activated CD8 T cells in vivo, using an agonist mAb, peripheral deletion is almost entirely inhibited. This occurs in the absence of an adjuvant or cytokine treatments. Thus, 4-1BB ligation can inhibit activation-induced cell death in vivo possibly by providing a long-term survival signal to activated T cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Mice

Female B10.A mice were purchased from the National Cancer Institute (Frederick, MD) and maintained in our animal facility under specific pathogen-free conditions.

Reagents, protocols, and Abs

Staphylococcal enterotoxin A (SEA) was purchased from Toxin Technology (Madison, WI) and administered to mice as i.p. injections of 0.30 µg. The agonist anti-4-1BB mAb 3H3 and biotinylated anti-4-1BB mAb 1D8 were used as a receptor agonist or staining reagent, respectively (17). As a control, rat IgG (Sigma, St. Louis, MO) was injected in doses equal to mAb 3H3.

Anti-TCR Vß3 was purified from hybridoma supernatants over protein G columns (Pharmacia, Piscataway, NJ) (19). The Ab was FITC-conjugated by us. FITC-conjugated anti-Vß14, PE-conjugated anti-CD4, PE-conjugated streptavidin, and biotinylated anti-TCR Vß3 were purchased from PharMingen (San Diego, CA). Red 613-conjugated anti-CD4 and Red 613-conjugated anti-CD8 were purchased from Life Technologies (Grand Island, NY).

Injection of SEA was at time 0 h, and all other injections were done in relation to SEA. In all experiments, 3H3 mAb was coinjected with SEA, and doses are described in the figure legends. Rat IgG was given to a control group at the same time as 3H3 mAb was given to an experimental group.

Cell processing and flow cytometry

Spleens were removed and teased through nylon mesh (Falcon, Becton Dickinson, Franklin Lakes, NJ) and subjected to ammonium chloride to lyse RBCs. Peripheral lymph nodes (LN) were teased into single-cell suspensions and washed with BSS. T cells from spleen or LN populations were purified on nylon wool columns as previously described (20).

For staining, cells were incubated on ice with a primary mAb in the presence of 5% normal mouse serum, culture supernatant containing anti-mouse Fc receptor mAb (24.G2), and 10 mg/ml human {gamma}-globulin (Sigma) to block nonspecific binding. After a 30 min incubation on ice in staining buffer (BSS, 3% FBS, 0.1% sodium azide), the cells were washed and analyzed by flow cytometry, or if a second step was necessary, the incubation and wash procedures were repeated. Analysis was conducted on an EPICS XL flow cytometer (Coulter Electronics, Miami, FL).

Cell viability counts were completed by trypan blue exclusion. Equal volumes of cells and trypan blue (PBS, 0.4% trypan blue, 0.2% NaN3) were mixed, and viable cells were counted.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
In an attempt to examine 4-1BB expression in vivo, mice were immunized with SEA, and activated T cells were evaluated for surface levels of 4-1BB. SEA is a SAg that binds MHC class II molecules on APC and stimulates T cells bearing TCR Vß3 (21, 22).

At 0, 0.5, 1.5, 3, 12, 24, and 48 h after SEA injection, LN T cells were purified and stained for CD4 or CD8, Vß3, and 4-1BB expression (Fig. 1Go). Flow cytometric analysis determined that 3-h activated CD4 Vß3 T cells do not express detectable levels of 4-1BB compared with the equivalent cell populations from noninjected mice. At 12 h, there is a profound increase in 4-1BB expression, and by 24 and 48 h levels of 4-1BB decrease. In contrast, SEA-activated CD8 Vß3 T cells began to express 4-1BB by 90 min and further at 3 h (Fig. 1Go). Peak expression occurred at 12 h followed by a decline to background levels by 48 h. Additionally, at 12 h the amount of 4-1BB appears to be higher on the CD8 over the CD4 T cells. However, it is also possible that the kinetics of peak expression is different between the two populations. We conclude that 4-1BB is rapidly expressed on both CD4 and CD8 SAg-stimulated T cells in vivo and that CD8 T cells express this molecule faster after stimulation than CD4 T cells.



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 1. Kinetics of 4-1BB expression on in vivo activated T cells. B10.A mice were injected with 0.30 µg of SEA. At various times after SEA injection, LN T cells were purified. These cells were stained for CD4 Vß3 4-1BB (left panel) and CD8 Vß3 4-1BB (right panel) and analyzed by flow cytometry (solid lines). 4-1BB expression on T cells from an uninjected normal mouse (dotted lines) is shown. This is one experiment similar to three others.

 
Upon stimulation with SAg, peripheral T cells will clonally expand and then delete (23, 24, 25). In the case of SEA, expansion of the Vß3 T cells is observed 2 days after injection (Fig. 2Go) (22). Compared with noninjected mice, a threefold increase in the frequency of splenic CD4 Vß3 T cells and a doubling, of those same cells, in absolute cell number was observed (Fig. 2Go, A and B). After expansion, there is a dramatic decrease in the frequency and absolute number of SEA-specific T cells. There is nearly a 10-fold decrease after peak expansion in both frequency and number of Vß3 T cells. The data show that the levels of SEA-specific T cells are lower than that found in uninjected mice. When SEA is injected with an agonist mAb specific for 4-1BB, clonal expansion of the CD4 Vß3 T cells is significantly increased (Fig. 2Go). Although deletion is inhibited to some degree based on absolute numbers, rescue is not observed based on frequency.



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 2. Time course of SEA-stimulated CD4 T cell deletion with and without 4-1BB activation. B10.A mice were coinjected with 0.10 mg of anti-4-1BB mAb 3H3 ({circ}) or 0.1 mg rat IgG ({square}) and 0.30 µg of SEA. Splenic T cells were purified on days 2, 5, 7, 12, and 21 after SEA injection. T cells were stained for CD4 Vß3 and analyzed by flow cytometry. Each point represents the mean percentages (A) and numbers (B) ± SEM from six mice over three separate experiments combined.

 
Analysis of SEA/4-1BB mAb-treated splenic CD8 T cells revealed that clonal expansion was not increased on day 2 after SEA injection in comparison to mice that received SEA alone (Fig. 3Go). Although the frequency of CD8 Vß3 T cells was slightly elevated (Fig. 3GoA), this effect was not observed when absolute numbers were examined (Fig. 3GoB). One explanation for this difference is the possibility that the CD8 T cells expanded further on day 3 or 4.



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 3. Time course of SEA-stimulated CD8 T cell deletion with and without 4-1BB activation. These data are from the experiments described in Fig. 2Go, except the cells were stained (A) and enumerated (B) for CD8 Vß3. Data from LN were similar (not shown).

 
When the latter time points were examined, it was observed that deletion was inhibited. There is practically no decrease in the number of CD8 Vß3 T cells between days 2 and 21 after SEA injection. On day 21, there are nearly 10-fold the number of Ag-specific CD8 T cells in the anti-4-1BB-treated mice in comparison to the control IgG-treated mice (Fig. 3GoB). As a control, Vß14 T cells were analyzed, and it was determined that the Vß14 T cells were unaffected by SEA and/or anti-4-1BB treatment (data not shown). Thus, 4-1BB ligation can provide a life signal to SAg-activated CD8 T cells that results in survival.

It is unclear why CD4 T cells were not rescued to the same degree from deletion as CD8 T cells. One possibility is that CD4 T cells are less responsive to 4-1BB ligation compared with CD8 T cells. There is at least one study that supports this notion (17).

These in vivo data demonstrate the effectiveness of 4-1BB ligation in preventing death of SAg-activated CD8 T cells; however, this model does not afford practical mechanistic studies due to the complication of in vivo analyses. To remedy this problem, an ex vivo model was employed. At the peak of SEA-induced clonal expansion, LN T cells were purified and cultured in vitro with no added stimuli. The cells were monitored for survival by counting the remaining number of viable CD8 Vß3 T cells at 0, 8, 12, and 16 h in culture. As a control, Vß14 T cells were stained, and the data show that these cells were unaltered regardless of the treatment (data not shown). On the other hand, CD8 Vß3 T cells from SEA/control IgG-treated mice preferentially died in vitro compared with equivalent cells from normal animals (Fig. 4Go). In contrast, CD8 Vß3 T cells from SEA/anti-4-1BB-treated mice preferentially survived compared with all other cell populations tested. This was not the case for SEA/control IgG cells, which decreased by greater than fourfold in absolute numbers over the 16-h incubation. In a separate experiment, we tested the idea that the rescued T cells were surviving due to IL-2 production. Our data indicate that IL-2 was not keeping these cells alive because a neutralizing IL-2 mAb did not block survival but was able to block IL-2-driven proliferation (data not shown). Nevertheless, it is possible that other survival factors were produced by the rescued cells.



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 4. Survival of SEA-stimulated and unstimulated CD8 T cells in vitro with and without 4-1BB activation. Three female B10.A mice were set up as follows: one was uninjected ({square}); one was injected with 0.20 mg of anti-4-1BB mAb 3H3 and 0.30 µg SEA ({circ}); and one was injected with 0.20 mg of rat IgG and 0.30 µg SEA ({diamond}). LN T cells were purified 2 days after injections and cultured at 2 x 106 cells per well in a 96-well plate. T cells were stained and enumerated for CD8 Vß14 (data not shown) and CD8 Vß3 expression at 0, 8, 12, and 16 h in culture. Each data point represents the mean numbers ± SEM from triplicate samples for each injection regimen. These data are comparable to three other experiments.

 
Experiments that forced ligation of CD28 by enhancing B7 expression on APC through CD40 ligation potently augmented SEA-specific CD8 T cell clonal expansion (6). Nevertheless, these cells went on to delete after expansion. This is in contrast to the data in these studies using 4-1BB as a costimulus. 4-1BB ligation was extremely potent at rescuing CD8 T cells from deletion after Ag recognition in vivo. These data are consistent with previously published in vitro data showing that 4-1BB ligation can inhibit activation-induced cell death (15).

The potency of the rescuing effect may have practical application, such as the design of CD8 T cell-based vaccines. Collectively, these data suggest that 4-1BB may be an integral component of CD8 T cell memory acquisition and may be a link between a putative danger signal and long-term immunity.


   Footnotes
 
1 This work was supported by grants from the Oregon Medical Research Foundation and the Linus Pauling Institute (A.T.V.). Back

2 Address correspondence and reprint requests to Dr. Anthony T. Vella, Department of Microbiology, 220 Nash Hall, Oregon State University, Corvallis, OR 97331. E-mail address: Back

3 Abbreviations used in this paper: SAg, superantigen; SEA, staphylococcal enterotoxin A; LN, lymph node. Back

Received for publication December 16, 1998. Accepted for publication February 9, 1999.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Jenkins, M. K., R. H. Schwartz. 1987. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 165:302.[Abstract/Free Full Text]
  2. Jenkins, M. K., D. M. Pardoll, J. Mizuguchi, H. Quill, R. H. Schwartz. 1987. T cell unresponsiveness in vivo and in vitro: fine specificity of induction and molecular characterization of the unresponsive state. Immunol. Rev. 95:113.[Medline]
  3. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, J. A. Ledbetter. 1991. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and IL-2 mRNA accumulation. J. Exp. Med. 173:721.[Abstract/Free Full Text]
  4. Jenkins, M. K., P. S. Taylor, S. D. Norton, K. B. Urdahl. 1991. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J. Immunol. 147:2461.[Abstract/Free Full Text]
  5. Fraser, J. D., B. A. Irving, G. R. Crabtree, A. Weiss. 1991. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 251:313.[Abstract/Free Full Text]
  6. Maxwell, R. J., J. D. Campbell, C. H. Kim, A. T. Vella. 1999. CD40 activation boosts immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion. J. Immunol. 162:2024.[Abstract/Free Full Text]
  7. Vella, A. T., T. Mitchell, B. Groth, P. S. Linsley, J. M. Green, C. B. Thompson, J. W. Kappler, P. Marrack. 1997. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J. Immunol. 158:4714.[Abstract]
  8. Roy, M., A. Aruffo, J. Ledbetter, P. Linsley, M. Kehry, R. Noelle. 1995. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur. J. Immunol. 25:596.[Medline]
  9. Matzinger, P.. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:991.[Medline]
  10. Vella, A. T., J. E. McCormack, P. S. Linsley, J. W. Kappler, P. Marrack. 1995. Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity 2:261.[Medline]
  11. Kuroda, K., J. Yagi, K. Imanishi, X. J. Yan, X. Y. Li, W. Fujimaki, H. Kato, T. Miyoshi-Akiyama, Y. Kumazawa, H. Abe, T. Uchiyama. 1996. Implantation of IL-2-containing osmotic pump prolongs the survival of SAg-reactive T cells expanded in mice injected with bacterial superantigen. J. Immunol. 157:1422.[Abstract]
  12. Vella, A. T., S. Dow, T. A. Potter, J. Kappler, P. Marrack. 1998. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95:3810.[Abstract/Free Full Text]
  13. Vinay, D. S., B. S. Kwon. 1998. Role of 4-1BB in immune responses. Semin. Immunol. 10:481.[Medline]
  14. Kwon, B. S., S. M. Weissman. 1989. cDNA sequences of two inducible T-cell genes. Proc. Natl. Acad. Sci. USA 86:1963.[Abstract/Free Full Text]
  15. Hurtado, J. C., Y. J. Kim, B. S. Kwon. 1997. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J. Immunol. 158:2600.[Abstract]
  16. DeBenedette, M. A., A. Shahinian, T. W. Mak, T. H. Watts. 1997. Costimulation of CD28- T lymphocytes by 4-1BB ligand. J. Immunol. 158:551.[Abstract]
  17. Shuford, W. W., K. Klussman, D. D. Tritchler, D. T. Loo, J. Chalupny, A. W. Siadak, T. J. Brown, J. Emswiler, H. Raecho, C. P. Larsen, T. C. Pearson, J. A. Ledbetter, A. Aruffo, R. S. Mittler. 1997. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186:47.[Abstract/Free Full Text]
  18. Melero, I., W. W. Shuford, S. A. Newby, A. Aruffo, J. A. Ledbetter, K. E. Hellstrom, R. S. Mittler, L. Chen. 1997. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3:682.[Medline]
  19. Pullen, A. M., P. Marrack, J. W. Kappler. 1988. The T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens. Nature 335:796.[Medline]
  20. Julius, M. H., E. Simpson, L. Herzenberg. 1973. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur. J. Immunol. 3:645.[Medline]
  21. Marrack, P. C., J. W. Kappler. 1990. The staphylococcal enterotoxins and their relatives. Science 248:705.[Abstract/Free Full Text]
  22. McCormack, J. E., J. E. Callahan, J. Kappler, P. Marrack. 1993. Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. J. Immunol. 150:3785.[Abstract]
  23. Webb, S., J. Sprent. 1990. Response of mature unprimed CD8+ T cells to Mlsa determinants. J. Exp. Med. 171:953.[Abstract/Free Full Text]
  24. MacDonald, H. S., S. Baschieri, R. K. Lees. 1991. Clonal expansion precedes anergy and death of Vß8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur. J. Immunol. 21:1963.[Medline]
  25. Liblau, R. S., R. Tisch, K. Shokat, X. Yang, N. Dumont, C. C. Goodnow, H. O. McDevitt. 1996. Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Proc. Natl. Acad. Sci. USA 93:3031.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
Y. Zhao, Q. J. Wang, S. Yang, J. N. Kochenderfer, Z. Zheng, X. Zhong, M. Sadelain, Z. Eshhar, S. A. Rosenberg, and R. A. Morgan
A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
J. Immunol., November 1, 2009; 183(9): 5563 - 5574.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Loisel-Meyer, T. Felizardo, J. Mariotti, M. E. Mossoba, J. E. Foley, R. Kammerer, N. Mizue, R. Keefe, J. A. McCart, W. Zimmermann, et al.
Potent induction of B- and T-cell immunity against human carcinoembryonic antigen-expressing tumors in human carcinoembryonic antigen transgenic mice mediated by direct lentivector injection
Mol. Cancer Ther., March 1, 2009; 8(3): 692 - 702.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. H. Y. Lin, B. J. Sedgmen, T. J. Moraes, L. M. Snell, D. J. Topham, and T. H. Watts
Endogenous 4-1BB Ligand Plays a Critical Role in Protection from Influenza-Induced Disease
J. Immunol., January 15, 2009; 182(2): 934 - 947.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Yan, B. D. Johnson, and R. J. Orentas
Induction of a VLA-2 (CD49b)-Expressing Effector T Cell Population by a Cell-Based Neuroblastoma Vaccine Expressing CD137L
J. Immunol., October 1, 2008; 181(7): 4621 - 4631.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Sabbagh, G. Pulle, Y. Liu, E. N. Tsitsikov, and T. H. Watts
ERK-Dependent Bim Modulation Downstream of the 4-1BB-TRAF1 Signaling Axis Is a Critical Mediator of CD8 T Cell Survival In Vivo
J. Immunol., June 15, 2008; 180(12): 8093 - 8101.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. J. Robertson, R. J. Messer, A. B. Carmody, R. S. Mittler, C. Burlak, and K. J. Hasenkrug
CD137 Costimulation of CD8+ T Cells Confers Resistance to Suppression by Virus-Induced Regulatory T Cells
J. Immunol., April 15, 2008; 180(8): 5267 - 5274.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D.-H. Kim, W.-S. Chang, Y.-S. Lee, K.-A Lee, Y.-K. Kim, B. S. Kwon, and C.-Y. Kang
4-1BB Engagement Costimulates NKT Cell Activation and Exacerbates NKT Cell Ligand-Induced Airway Hyperresponsiveness and Inflammation
J. Immunol., February 15, 2008; 180(4): 2062 - 2068.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Wang, T. Wen, J.-P. Routy, N. F. Bernard, R. P. Sekaly, and T. H. Watts
4-1BBL Induces TNF Receptor-Associated Factor 1-Dependent Bim Modulation in Human T Cells and Is a Critical Component in the Costimulation-Dependent Rescue of Functionally Impaired HIV-Specific CD8 T Cells
J. Immunol., December 15, 2007; 179(12): 8252 - 8263.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
M. Habib-Agahi, T. T. Phan, and P. F. Searle
Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells
Int. Immunol., December 1, 2007; 19(12): 1383 - 1394.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. H. Yi, H. Nechushtan, W. J. Bowers, G. R. Walker, Y. Zhang, D. G. Pham, E. R. Podack, H. J. Federoff, K. A. Tolba, and J. D. Rosenblatt
Adoptively Transferred Tumor-Specific T Cells Stimulated Ex vivo Using Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor Activity In vivo
Cancer Res., October 15, 2007; 67(20): 10027 - 10037.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. S. Vinay, J. D. Kim, T. Asai, B. K. Choi, and B. S. Kwon
Absence of 4 1BB Gene Function Exacerbates Lacrimal Gland Inflammation in Autoimmune-Prone MRL-Faslpr Mice
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4608 - 4615.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Zhang, K. M. Snyder, M. M. Suhoski, M. V. Maus, V. Kapoor, C. H. June, and C. L. Mackall
4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy
J. Immunol., October 1, 2007; 179(7): 4910 - 4918.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S.-J. Lee, R. J. Rossi, S.-K. Lee, M. Croft, B. S. Kwon, R. S. Mittler, and A. T. Vella
CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent
J. Immunol., August 15, 2007; 179(4): 2203 - 2214.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Kim, H. J. Kim, K. Park, J. Kim, H.-J. Choi, H. Yagita, S. H. Nam, H. R. Cho, and B. Kwon
Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease
Blood, July 15, 2007; 110(2): 776 - 782.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Fuse, S. Bellfy, H. Yagita, and E. J. Usherwood
CD8+ T Cell Dysfunction and Increase in Murine Gammaherpesvirus Latent Viral Burden in the Absence of 4-1BB Ligand
J. Immunol., April 15, 2007; 178(8): 5227 - 5236.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Niu, S. Strahotin, B. Hewes, B. Zhang, Y. Zhang, D. Archer, T. Spencer, D. Dillehay, B. Kwon, L. Chen, et al.
Cytokine-Mediated Disruption of Lymphocyte Trafficking, Hemopoiesis, and Induction of Lymphopenia, Anemia, and Thrombocytopenia in Anti-CD137-Treated Mice
J. Immunol., April 1, 2007; 178(7): 4194 - 4213.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. T. Chow, S. Dhanji, J. Cross, P. Johnson, and H.-S. Teh
H2-M3-Restricted T Cells Participate in the Priming of Antigen-Specific CD4+ T Cells
J. Immunol., October 15, 2006; 177(8): 5098 - 5104.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Sun, S. E. Blink, W. Liu, Y. Lee, B. Chen, J. Solway, J. Weinstock, L. Chen, and Y.-X. Fu
Inhibition of Th2-Mediated Allergic Airway Inflammatory Disease by CD137 Costimulation
J. Immunol., July 15, 2006; 177(2): 814 - 821.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Pulle, M. Vidric, and T. H. Watts
IL-15-Dependent Induction of 4-1BB Promotes Antigen-Independent CD8 Memory T Cell Survival.
J. Immunol., March 1, 2006; 176(5): 2739 - 2748.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
L. Myers, S. W. Lee, R. J. Rossi, L. Lefrancois, B. S. Kwon, R. S. Mittler, M. Croft, and A. T. Vella
Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells
Int. Immunol., February 1, 2006; 18(2): 325 - 333.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. D. Vu, M. R. Clarkson, H. Yagita, L. A. Turka, M. H. Sayegh, and X. C. Li
Critical, but Conditional, Role of OX40 in Memory T Cell-Mediated Rejection
J. Immunol., February 1, 2006; 176(3): 1394 - 1401.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Vidric, W.-K. Suh, U. Dianzani, T. W. Mak, and T. H. Watts
Cooperation between 4-1BB and ICOS in the Immune Response to Influenza Virus Revealed by Studies of CD28/ICOS-Deficient Mice
J. Immunol., December 1, 2005; 175(11): 7288 - 7296.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Serghides, J. Bukczynski, T. Wen, C. Wang, J.-P. Routy, M.-R. Boulassel, R.-P. Sekaly, M. Ostrowski, N. F. Bernard, and T. H. Watts
Evaluation of OX40 Ligand as a Costimulator of Human Antiviral Memory CD8 T Cell Responses: Comparison with B7.1 and 4-1BBL
J. Immunol., November 15, 2005; 175(10): 6368 - 6377.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Bukczynski, T. Wen, C. Wang, N. Christie, J.-P. Routy, M.-R. Boulassel, C. M. Kovacs, K. S. MacDonald, M. Ostrowski, R.-P. Sekaly, et al.
Enhancement of HIV-Specific CD8 T Cell Responses by Dual Costimulation with CD80 and CD137L
J. Immunol., November 15, 2005; 175(10): 6378 - 6389.
[Abstract] [Full Text] [PDF]

Home page
 Phil Trans R Soc BHome page
B. R Blazar and W. J Murphy
Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)
Phil Trans R Soc B, September 29, 2005; 360(1461): 1747 - 1767.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Hendriks, Y. Xiao, J. W. A. Rossen, K. F. van der Sluijs, K. Sugamura, N. Ishii, and J. Borst
During Viral Infection of the Respiratory Tract, CD27, 4-1BB, and OX40 Collectively Determine Formation of CD8+ Memory T Cells and Their Capacity for Secondary Expansion
J. Immunol., August 1, 2005; 175(3): 1665 - 1676.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Myers, M. Croft, B. S. Kwon, R. S. Mittler, and A. T. Vella
Peptide-Specific CD8 T Regulatory Cells Use IFN-{gamma} to Elaborate TGF-{beta}-Based Suppression
J. Immunol., June 15, 2005; 174(12): 7625 - 7632.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Kim, W. S. Choi, S. La, J.-H. Suh, B.-S. Kim, H. R. Cho, B. S. Kwon, and B. Kwon
Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells
Blood, March 1, 2005; 105(5): 2206 - 2213.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K.-O. Nam, H. Kang, S.-M. Shin, K.-H. Cho, B. Kwon, B. S. Kwon, S.-J. Kim, and H.-W. Lee
Cross-Linking of 4-1BB Activates TCR-Signaling Pathways in CD8+ T Lymphocytes
J. Immunol., February 15, 2005; 174(4): 1898 - 1905.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
H. Shao, Y. Fu, T. Liao, Y. Peng, L. Chen, H. J. Kaplan, and D. Sun
Anti-CD137 mAb Treatment Inhibits Experimental Autoimmune Uveitis by Limiting Expansion and Increasing Apoptotic Death of Uveitogenic T Cells
Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 596 - 603.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-J. Kim, T. M. Stringfield, Y. Chen, and H. E. Broxmeyer
Modulation of cord blood CD8+ T-cell effector differentiation by TGF-{beta}1 and 4-1BB costimulation
Blood, January 1, 2005; 105(1): 274 - 281.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. Dawicki, E. M. Bertram, A. H. Sharpe, and T. H. Watts
4-1BB and OX40 Act Independently to Facilitate Robust CD8 and CD4 Recall Responses
J. Immunol., November 15, 2004; 173(10): 5944 - 5951.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S.-J. Lee, L. Myers, G. Muralimohan, J. Dai, Y. Qiao, Z. Li, R. S. Mittler, and A. T. Vella
4-1BB and OX40 Dual Costimulation Synergistically Stimulate Primary Specific CD8 T Cells for Robust Effector Function
J. Immunol., September 1, 2004; 173(5): 3002 - 3012.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. D. Vu, F. Amanullah, Y. Li, G. Demirci, M. H. Sayegh, and X. C. Li
Different Costimulatory and Growth Factor Requirements for CD4+ and CD8+ T Cell-Mediated Rejection
J. Immunol., July 1, 2004; 173(1): 214 - 221.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Bukczynski, T. Wen, K. Ellefsen, J. Gauldie, and T. H. Watts
Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses
PNAS, February 3, 2004; 101(5): 1291 - 1296.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
H. M. Toennies, J. M. Green, and R. H. Arch
Expression of CD30 and Ox40 on T lymphocyte subsets is controlled by distinct regulatory mechanisms
J. Leukoc. Biol., February 1, 2004; 75(2): 350 - 357.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. M. Bertram, W. Dawicki, B. Sedgmen, J. L. Bramson, D. H. Lynch, and T. H. Watts
A Switch in Costimulation from CD28 to 4-1BB during Primary versus Secondary CD8 T Cell Response to Influenza In Vivo
J. Immunol., January 15, 2004; 172(2): 981 - 988.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. M. Finney, A. N. Akbar, and A. D. G. Lawson
Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCR{zeta} Chain
J. Immunol., January 1, 2004; 172(1): 104 - 113.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. A. Wilcox, K. Tamada, D. B. Flies, G. Zhu, A. I. Chapoval, B. R. Blazar, W. M. Kast, and L. Chen
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo
Blood, January 1, 2004; 103(1): 177 - 184.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Murillo, A. Arina, I. Tirapu, C. Alfaro, G. Mazzolini, B. Palencia, A. L.-D. De Cerio, J. Prieto, M. Bendandi, and I. Melero
Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies
Clin. Cancer Res., November 15, 2003; 9(15): 5454 - 5464.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
G. Rajagopalan, Y. C. Kudva, L. Chen, L. Wen, and C. S. David
Autoimmune diabetes in HLA-DR3/DQ8 transgenic mice expressing the co-stimulatory molecule B7-1 in the {beta} cells of islets of Langerhans
Int. Immunol., September 1, 2003; 15(9): 1035 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Li, A. Carr, F. Ito, S. Teitz-Tennenbaum, and A. E. Chang
Polarization Effects of 4-1BB during CD28 Costimulation in Generating Tumor-reactive T Cells for Cancer Immunotherapy
Cancer Res., May 15, 2003; 63(10): 2546 - 2552.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Myers, C. Takahashi, R. S. Mittler, R. J. Rossi, and A. T. Vella
Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering
PNAS, April 29, 2003; 100(9): 5348 - 5353.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. J. Shedlock, J. K. Whitmire, J. Tan, A. S. MacDonald, R. Ahmed, and H. Shen
Role of CD4 T Cell Help and Costimulation in CD8 T Cell Responses During Listeria monocytogenes Infection
J. Immunol., February 15, 2003; 170(4): 2053 - 2063.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. W. Lillard Jr, U. P. Singh, P. N. Boyaka, S. Singh, D. D. Taub, and J. R. McGhee
MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity
Blood, February 1, 2003; 101(3): 807 - 814.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Berger, C. A. Blau, T. Clackson, S. R. Riddell, and S. Heimfeld
CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy
Blood, January 15, 2003; 101(2): 476 - 484.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H.-W. Lee, S.-J. Park, B. K. Choi, H. H. Kim, K.-O. Nam, and B. S. Kwon
4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-1
J. Immunol., November 1, 2002; 169(9): 4882 - 4888.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Bansal-Pakala and M. Croft
Defective T Cell Priming Associated with Aging Can Be Rescued by Signaling Through 4-1BB (CD137)
J. Immunol., November 1, 2002; 169(9): 5005 - 5009.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-J. Kim, R. R. Brutkiewicz, and H. E. Broxmeyer
Role of 4-1BB (CD137) in the functional activation of cord blood CD28-CD8+ T cells
Blood, October 16, 2002; 100(9): 3253 - 3260.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
D. Laderach, M. Movassagh, A. Johnson, R. S. Mittler, and A. Galy
4-1BB co-stimulation enhances human CD8+ T cell priming by augmenting the proliferation and survival of effector CD8+ T cells
Int. Immunol., October 1, 2002; 14(10): 1155 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. E. Miller, J. Jones, T. Le, J. Whitmore, N. Boiani, B. Gliniak, and D. H. Lynch
4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner
J. Immunol., August 15, 2002; 169(4): 1792 - 1800.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Pauly, K. Broll, M. Wittmann, G. Giegerich, and H. Schwarz
CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers
J. Leukoc. Biol., July 1, 2002; 72(1): 35 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. F. May Jr., L. Chen, P. Zheng, and Y. Liu
Anti-4-1BB Monoclonal Antibody Enhances Rejection of Large Tumor Burden by Promoting Survival but not Clonal Expansion of Tumor-specific CD8+ T Cells
Cancer Res., June 1, 2002; 62(12): 3459 - 3465.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Wen, J. Bukczynski, and T. H. Watts
4-1BB Ligand-Mediated Costimulation of Human T Cells Induces CD4 and CD8 T Cell Expansion, Cytokine Production, and the Development of Cytolytic Effector Function
J. Immunol., May 15, 2002; 168(10): 4897 - 4906.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. A. Wilcox, A. I. Chapoval, K. S. Gorski, M. Otsuji, T. Shin, D. B. Flies, K. Tamada, R. S. Mittler, H. Tsuchiya, D. M. Pardoll, et al.
Expression of Functional CD137 Receptor by Dendritic Cells
J. Immunol., May 1, 2002; 168(9): 4262 - 4267.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. R. Maxwell, C. Ruby, N. I. Kerkvliet, and A. T. Vella
Contrasting the Roles of Costimulation and the Natural Adjuvant Lipopolysaccharide During the Induction of T Cell Immunity
J. Immunol., May 1, 2002; 168(9): 4372 - 4381.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Demirci, W. Gao, X. X. Zheng, T. R. Malek, T. B. Strom, and X. C. Li
On CD28/CD40 Ligand Costimulation, Common {gamma}-Chain Signals, and the Alloimmune Response
J. Immunol., May 1, 2002; 168(9): 4382 - 4390.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. J. D. van Mierlo, A. Th. den Boer, J. P. Medema, E. I. H. van der Voort, M. F. Fransen, R. Offringa, C. J. M. Melief, and R. E. M. Toes
CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity
PNAS, April 16, 2002; 99(8): 5561 - 5566.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Diehl, G. J. D. van Mierlo, A. T. den Boer, E. van der Voort, M. Fransen, L. van Bostelen, P. Krimpenfort, C. J. M. Melief, R. Mittler, R. E. M. Toes, et al.
In Vivo Triggering Through 4-1BB Enables Th-Independent Priming of CTL in the Presence of an Intact CD28 Costimulatory Pathway
J. Immunol., April 15, 2002; 168(8): 3755 - 3762.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. M. Bertram, P. Lau, and T. H. Watts
Temporal Segregation of 4-1BB Versus CD28-Mediated Costimulation: 4-1BB Ligand Influences T Cell Numbers Late in the Primary Response and Regulates the Size of the T Cell Memory Response Following Influenza Infection
J. Immunol., April 15, 2002; 168(8): 3777 - 3785.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Yamada, A. D. Salama, and M. H. Sayegh
The Role of Novel T Cell Costimulatory Pathways in Autoimmunity and Transplantation
J. Am. Soc. Nephrol., February 1, 2002; 13(2): 559 - 575.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. Sun, X. Lin, H. M. Chen, Q. Wu, S. K. Subudhi, L. Chen, and Y.-X. Fu
Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis
J. Immunol., February 1, 2002; 168(3): 1457 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Nozawa, J. Ohata, J. Sakurai, H. Hashimoto, H. Miyajima, H. Yagita, K. Okumura, and M. Azuma
Preferential Blockade of CD8+ T Cell Responses by Administration of Anti-CD137 Ligand Monoclonal Antibody Results in Differential Effect on Development of Murine Acute and Chronic Graft-Versus-Host Diseases
J. Immunol., November 1, 2001; 167(9): 4981 - 4986.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Zhu, D. B. Flies, K. Tamada, Y. Sun, M. Rodriguez, Y.-X. Fu, and L. Chen
Progressive Depletion of Peripheral B Lymphocytes in 4-1BB (CD137) Ligand/I-E{alpha}-Transgenic Mice
J. Immunol., September 1, 2001; 167(5): 2671 - 2676.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. L. Cannons, P. Lau, B. Ghumman, M. A. DeBenedette, H. Yagita, K. Okumura, and T. H. Watts
4-1BB Ligand Induces Cell Division, Sustains Survival, and Enhances Effector Function of CD4 and CD8 T Cells with Similar Efficacy
J. Immunol., August 1, 2001; 167(3): 1313 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. A. Kim, B. J. Averbook, K. Chambers, K. Rothchild, J. Kjaergaard, R. Papay, and S. Shu
Divergent Effects of 4-1BB Antibodies on Antitumor Immunity and on Tumor-reactive T-Cell Generation
Cancer Res., March 1, 2001; 61(5): 2031 - 2037.
[Abstract] [Full Text]

Home page
 J. Immunol.Home page
B. R. Blazar, B. S. Kwon, A. Panoskaltsis-Mortari, K. B. Kwak, J. J. Peschon, and P. A. Taylor
Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients
J. Immunol., March 1, 2001; 166(5): 3174 - 3183.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. L. Cannons, Y. Choi, and T. H. Watts
Role of TNF Receptor-Associated Factor 2 and p38 Mitogen-Activated Protein Kinase Activation During 4-1BB-Dependent Immune Response
J. Immunol., December 1, 2000; 165(11): 6193 - 6204.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. Gramaglia, A. Jember, S. D. Pippig, A. D. Weinberg, N. Killeen, and M. Croft
The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion
J. Immunol., September 15, 2000; 165(6): 3043 - 3050.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
R. S. Kornbluth
The emerging role of CD40 ligand in HIV infection
J. Leukoc. Biol., September 1, 2000; 68(3): 373 - 382.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. R. Salih, S. G. Kosowski, V. F. Haluska, G. C. Starling, D. T. Loo, F. Lee, A. A. Aruffo, P. A. Trail, and P. A. Kiener
Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells
J. Immunol., September 1, 2000; 165(5): 2903 - 2910.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. T. Tan, J. K. Whitmire, K. Murali-Krishna, R. Ahmed, J. D. Altman, R. S. Mittler, A. Sette, T. C. Pearson, and C. P. Larsen
4-1BB Costimulation Is Required for Protective Anti-Viral Immunity After Peptide Vaccination
J. Immunol., March 1, 2000; 164(5): 2320 - 2325.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
I. Suzuki and P. J. Fink
The dual functions of Fas ligand in the regulation of peripheral CD8+ and CD4+ T cells
PNAS, February 15, 2000; 97(4): 1707 - 1712.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. D. Pippig, C. Pena-Rossi, J. Long, W. R. Godfrey, D. J. Fowell, S. L. Reiner, M. L. Birkeland, R. M. Locksley, A. N. Barclay, and N. Killeen
Robust B Cell Immunity but Impaired T Cell Proliferation in the Absence of CD134 (OX40)
J. Immunol., December 15, 1999; 163(12): 6520 - 6529.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
R. S. Mittler, T. S. Bailey, K. Klussman, M. D. Trailsmith, and M. K. Hoffmann
Anti-4-1bb Monoclonal Antibodies Abrogate T Cell-Dependent Humoral Immune Responses in Vivo through the Induction of Helper T Cell Anergy
J. Exp. Med., November 15, 1999; 190(10): 1535 - 1540.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. J. D. van Mierlo, A. Th. den Boer, J. P. Medema, E. I. H. van der Voort, M. F. Fransen, R. Offringa, C. J. M. Melief, and R. E. M. Toes
CD40 stimulation leads to effective therapy of CD40- tumors through induction of strong systemic cytotoxic T lymphocyte immunity
PNAS, April 16, 2002; 99(8): 5561 - 5566.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
N. Arbour, D. Naniche, D. Homann, R. J. Davis, R. A. Flavell, and M. B.A. Oldstone
c-Jun NH2-Terminal Kinase (JNK)1 and JNK2 Signaling Pathways Have Divergent Roles in CD8+ T Cell-mediated Antiviral Immunity
J. Exp. Med., March 25, 2002; 195(7): 801 - 810.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahashi, C.
Right arrow Articles by Vella, A. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, C.
Right arrow Articles by Vella, A. T.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS